- Home
- HLNE vs NUVL Comparison
HLNE vs NUVL Comparison
Compare HLNE & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLNE
- NUVL
- Stock Information
- Founded
- HLNE 1991
- NUVL 2017
- Country
- HLNE United States
- NUVL United States
- Employees
- HLNE N/A
- NUVL 200
- Industry
- HLNE Investment Managers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- HLNE Finance
- NUVL Health Care
- Exchange
- HLNE Nasdaq
- NUVL Nasdaq
- Market Cap
- HLNE 5.6B
- NUVL 6.5B
- IPO Year
- HLNE 2017
- NUVL 2021
- Fundamental
- Price
- HLNE $118.13
- NUVL $91.41
- Analyst Decision
- HLNE Hold
- NUVL Strong Buy
- Analyst Count
- HLNE 9
- NUVL 10
- Target Price
- HLNE $162.11
- NUVL $120.50
- AVG Volume (30 Days)
- HLNE 567.0K
- NUVL 414.7K
- Earning Date
- HLNE 11-04-2025
- NUVL 11-11-2025
- Dividend Yield
- HLNE 1.79%
- NUVL N/A
- EPS Growth
- HLNE 18.07
- NUVL N/A
- EPS
- HLNE 5.15
- NUVL N/A
- Revenue
- HLNE $692,190,000.00
- NUVL N/A
- Revenue This Year
- HLNE $5.18
- NUVL N/A
- Revenue Next Year
- HLNE $17.29
- NUVL N/A
- P/E Ratio
- HLNE $23.37
- NUVL N/A
- Revenue Growth
- HLNE 10.66
- NUVL N/A
- 52 Week Low
- HLNE $114.63
- NUVL $55.54
- 52 Week High
- HLNE $203.72
- NUVL $105.13
- Technical
- Relative Strength Index (RSI)
- HLNE 29.87
- NUVL 62.84
- Support Level
- HLNE $114.63
- NUVL $84.62
- Resistance Level
- HLNE $127.26
- NUVL $89.87
- Average True Range (ATR)
- HLNE 4.47
- NUVL 3.76
- MACD
- HLNE -0.49
- NUVL 0.52
- Stochastic Oscillator
- HLNE 13.58
- NUVL 86.14
About HLNE Hamilton Lane Incorporated
Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.